PBE News and Press, Invesco Dynamic Biotech & Genome From 06/21/19

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...

Array BioPharma is  up 56%  after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is  higher by 8.35%  after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'...

With yet another US Senate hearing having been held in late February , prescription drug prices have been continuously receiving a lot of attention. While an eventual solution to brand name pricing may take a number of years, changes to the generic industry may be coming quicker. Over the pas...

( Thank you for the bone crushing pic ) It’s finally here! No, not spring but the return of “Biotech Merger Mania – 2019 Edition!” At least that’s the theme that’s been hyped throughout the financial media over the last few days as speculation began ...

By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil. The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences...